Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Two-Stage, Open-Label Phase 2 Study of Pracinostat and Azacitidine in Patients With IPSS-R High and Very High Risk Myelodysplastic Syndromes Previously Untreated With Hypomethylating Agents

NCT03151304 is registered in ClinicalTrials.gov with Helsinn Healthcare SA as lead sponsor.

NCT NCT03151304
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03151304 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Two-Stage, Open-Label Phase 2 Study of Pracinostat and Azacitidine in Patients With IPSS-R High and Very High Risk Myelodysplastic Syndromes Previously Untreated With Hypomethylating Agents
Lead sponsor
Helsinn Healthcare SA
Phase
Phase 2
Overall status
Terminated
Start date
June 1, 2017
Completion date
December 1, 2020
Enrollment
64 (actual)
Sites
25

Conditions

As the registry lists them; a condition with its own page is linked.

myelodysplastic syndromes